CompletedPhase 1NCT00620295

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Studying Bone sarcoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Masonic Cancer Center, University of Minnesota
Principal Investigator: Arkadiusz Dudek, MD
Masonic Cancer Center, University of Minnesota
Intervention: bortezomib(drug)
Enrollment: 17 enrolled
Eligibility: 70 years · All sexes
Timeline: 2007 – 2009

Study locations (1)

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00620295 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials